How Often Do I Take Egrifta

Here's a taste of what TheBody.com has to offer on this topic:

Ask the Experts

Nelson, what's going on with Egrifta?

I am on ADAP. Can I get it now? My lipodystrophy belly is pretty big and I need to do something about itCarlos...

Response from Nelson Vergel, B.S.Ch.E., M.B.A.

Program for Wellness Restoration

CarlosSerono launched Egrifta this month.Doctors are calling in the number included in the link below to get the paper work started for insurance reimbursement.It seems that some insurance companies are already starting to pay for it, but high... Read more »

joint pain for egrifta

hi., i been using egrifta for the last 2 months , when i start seeing results , my both hands,... Read more »

Response from Keith Henry, M.D. »

Serostim vs Egrifta

My insurance company will pay for Serostim but not Egrifta.(not yet on their list of acceptable... Read more »

Response from Keith Henry, M.D. »

Go to Ask the Experts »

Articles

FDA Approves Egrifta for Treatment of Lipodystrophy in People With HIV

On November 10, 2010, the Food and Drug Administration approved Egrifta (tesamorelin) to treat HIV patients with lipodystrophy, a condition in which excess fat develops in different areas of the body, most notably around the liver, stomach, and... Read more »

Tesamorelin Approved for Lipodystrophy

In November, the FDA approved tesamorelin (Egrifta; formerly known as TH9507) for treatment of a type of lipodystrophy in HIV positive people taking antiretroviral therapy. Tesamorelin is a synthetic growth hormone-releasing factor that stimulates... Read more »

Belly Fat Drug Debated Even Before FDA Approval

Drugs into bodies ... not as clearcut as it sounds. Tesamorelin (expected to be called "Egrifta" if and when it is marketed and sold in the United States by the company EMD Serono) is an experimental drug that seeks to limit or reduce belly fat... Read more »

New Treatment for Excess Deep Belly Fat Approved

In November 2010, a new drug called tesamorelin (Egrifta) was approved by the FDA to treat excess deep belly fat in HIV-positive people. The drug is a synthetic human growth hormone releasing factor that stimulates the pituitary gland to make growth... Read more »

Connect With Others

Egrifta tesamorelin, is it available?

Posted by artnut, 2 Replies

Positively Aware has an article (July/August 2010)on the FDA approving Egrifta for the treatment of belly fat. Is it available? Has anyone had any experience with it? The biggest problem seems injecting oneself. How about blood sugar levels? ... Read more »

Egrifta

Posted by Jameser, 4 Replies

I have been diagnosed with HIV associated lipodystrophy causing a huge belly. I'm 27 years old and I've tried exercise, changing my diet, among other things to try to lose the belly. I recently talked to my doctor about starting Egrifta and he... Read more »

Egrifta /tesamorelin

Posted by ricky1, 1 Reply

I was diagnosed with lypodystrophy my dr referred me to an epidemiologist for help 2 years ago,My insrence company will cover it.but I had to go through a third party that will help pay for the copay. I was in a study with serostim but the... Read more »

Connect on Our Bulletin Boards »

Tools

My Health Tracker

Assess Your Risk for HIV

Find Local HIV/AIDS Services

Resource Centers

Guides for People With HIV

View All of Our Guides >>

Related Topics

View More HIV/AIDS-Related Topics »

The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.